Pharmaceutical Control of the
Human Microbiome

Overview

Symberix, Inc. is a biotechnology company focused on the development of first-to-market drugs that selectively target the human microbiome. Intestinal bacteria play critical roles in digestion, metabolism, tissue repair, immune development, vitamin synthesis and many other key functions.

The initial focus of Symberix is the development of two novel drugs that selectively inhibit a bacterial enzyme responsible for clinically serious side effects of certain pain and cancer medications. In the United States, more than $2 billion is spent annually to treat adverse drug reactions originating in the lower gastrointestinal tract from chemotherapeutic agents and NSAIDs.